Search results for "Coherence"

showing 10 items of 905 documents

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Colla…

2014

Purpose: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. Methods: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). Results: There were 24 girls and 15 boys with group median age of 13 years (range, 3–17 years). Mean follow-up period was 12.8 months (range, 3–60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabAdolescentVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedOphthalmologyRanibizumabmedicineHumansChildRetrospective StudiesRetinabusiness.industryRetrospective cohort studyGeneral Medicineeye diseasesChoroidal NeovascularizationClinical trialBevacizumabOphthalmologyChoroidal neovascularizationmedicine.anatomical_structureTreatment OutcomeChild PreschoolIntravitreal InjectionsEtiologyFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retin…

2016

To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabVisual AcuityAngiogenesis InhibitorsOphthalmoscopy03 medical and health sciencesMacular Degeneration0302 clinical medicineOphthalmologyGeographic AtrophymedicineHumans030212 general & internal medicineFluorescein AngiographyAfliberceptAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesChoroidal NeovascularizationBevacizumabOphthalmoscopyOphthalmologyChoroidal neovascularizationTreatment OutcomeIntravitreal Injections030221 ophthalmology & optometryFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients

2015

Purpose In response to anti-VEGF treatment for wet AMD retinal anatomy and visual acuity is often remedied. In our previous study, we showed that visual evoked potentials (VEP) improve following successful anti-VEGF treatment. The aim of this study was to investigate, how visual acuity and retinal thickness changes are reflected in VEP parameters. Moreover, we wanted to assess the feasibility of VEP as a novel monitoring tool for wet AMD patients. Methods A total of 16 patients and six control subjects were enrolled in this study. Patients received three bevacizumab intravitreal injections. At the beginning of the study and four to 6 weeks after the last injection, the best-corrected visual…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresexudative age-related macular degenerationvisual acuityAngiogenesis InhibitorsVisual systemRetinaVisual processingchemistry.chemical_compoundOphthalmologyMedicineHumansVisual PathwaysProspective Studiesage-related eye diseasesProspective cohort studyAgedVisual CortexBest corrected visual acuityAged 80 and overRetinaoptical coherence tomographybusiness.industryRetinalta3141General MedicineOrgan Sizeeye diseasesta3125BevacizumabOphthalmologymedicine.anatomical_structureVisual cortexchemistryIntravitreal InjectionsWet Macular DegenerationOptometryEvoked Potentials VisualFemalesense organsmedicine.symptomvisual evoked potentialbusinessTomography Optical CoherenceActa Ophthalmologica
researchProduct

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular ede…

2013

To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C).In all 3 groups, the authors observed improvement of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresDiabetic macular edemaVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular EdemaOphthalmologymedicineHumansIn patientIntravitreal bevacizumabRetrospective StudiesRetinaDiabetic RetinopathyLaser Coagulationbusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapyeye diseasesbody regionsBevacizumabOphthalmologymedicine.anatomical_structureTreatment OutcomeIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceRetina (Philadelphia, Pa.)
researchProduct

Is Ranibizumab effective in stopping the loss of vision for Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study

2010

Aim To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM). Design Prospective, multicentre, interventional case series. Methods 40 eyes of 39 consecutive patients with PM and CNV were treated with ‘on demand’ intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results Mean age was 53±13 years and mean refractive error –13.5±6.5 D. Median follow-up was 13.3±2 (range 12–18) months. Fifteen eyes (37.5%) had previou…

MaleVisual Acuity/drug effectsRefractive errorgenetic structuresEye diseaseVisual AcuityVision disorderProspective StudiesFluorescein AngiographyMedicine(all)Neovascularisationmedicine.diagnostic_testAntibodies MonoclonalDrugsDiabetic retinopathyMiddle AgedFluorescein angiographySensory SystemsChoroidal neovascularizationmedicine.anatomical_structureMyopia DegenerativeIntravitreal InjectionsFemaleMyopia Degenerative/complicationsmedicine.symptomTomography Optical Coherencemedicine.drugAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedAntibodies Monoclonal/administration & dosageCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansAgedbusiness.industryChoroidChoroidal Neovascularization/drug therapyOff-Label Usemedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyChoroidsense organsRanibizumabaged 80 and overbusinessFollow-Up Studies
researchProduct

Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

2019

Purpose: To analyse the effects of intravitreal dexamethasone implant (DEX) in patients with diabetic macular oedema (DME) unresponsive to ranibizumab treatment, in relation to the inflammatory optical coherence tomography (OCT) retinal features, subfoveal neuroretinal detachment (SND) and hyperreflective retinal spots (HRS). Methods: Patients with DME poorly responsive to three injections of ranibizumab were treated with DEX. Best-corrected visual acuity (BCVA) and central macula thickness (CMT, measured by Spectralis SD-OCT) were assessed at baseline and at 1, 3, and 6 months. Results: Overall, 44 eyes were included in the study. In the whole group, mean BCVA (baseline 51.5 ± 8.3 letters)…

MaleVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsDrug Implantchemistry.chemical_compound0302 clinical medicineGlucocorticoidMacula LuteaProspective StudiesFluorescein AngiographyProspective cohort studyTomographyDrug Implantsmedicine.diagnostic_testGeneral MedicineDiabetic retinopathyDrug ToleranceFluorescein angiographyTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalemedicine.symptomDrugTomography Optical Coherencemedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyFundus Oculibest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography Optical Coherence; Treatment Outcome; Visual AcuitydexamethasoneMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesOphthalmologyRanibizumabmedicineHumansMacular edemaGlucocorticoidsDexamethasoneAgedbest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship; Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography; Optical Coherence; Treatment Outcome; Visual Acuityoptical coherence tomographyDiabetic RetinopathyDose-Response Relationship Drugbusiness.industryIntravitreal InjectionRetinalmedicine.diseaseeye diseasesOphthalmologyProspective StudiechemistryOptical Coherence030221 ophthalmology & optometrysense organsRanibizumabbusinessdiabetes retinopathy030217 neurology & neurosurgerybest-corrected visual acuityFollow-Up Studies
researchProduct

Sense of coherence: effect on adherence and response to resistance training in older people with hip fracture history.

2013

Our aim was to study the effects of sense of coherence (SOC) on training adherence and interindividual changes in muscle strength, mobility, and balance after resistance training in older people with hip fracture history. These are secondary analyses of a 12-week randomized controlled trial of progressive resistance training in 60- to 85-year-old community-dwelling people 0.5–7 years after hip fracture (n = 45; ISRCTN34271567). Pre- and posttrial assessments included SOC, knee extension strength, walking speed, timed up-and-go (TUG), and Berg Balance Scale (BBS). Group-by-SOC interaction effects (repeated-measures ANOVA) were statistically significant for TUG (p = .005) and BBS (p = .040), …

Malemedicine.medical_specialtyActivities of daily livingSense of Coherencemedicine.medical_treatmentPhysical Therapy Sports Therapy and RehabilitationPhysical exerciseWalkinglaw.inventionSocial supportPhysical medicine and rehabilitationRandomized controlled triallawActivities of Daily LivingOutcome Assessment Health CaremedicineHumansMuscle StrengthMobility LimitationFinlandAgedAged 80 and overHip fractureRehabilitationbusiness.industryHip FracturesRehabilitationSocial SupportResistance Trainingmedicine.diseasePreferred walking speedBerg Balance ScalePhysical therapyPatient ComplianceFemaleIndependent LivingGeriatrics and GerontologybusinessGerontologyNeeds AssessmentJournal of aging and physical activity
researchProduct

Comparison of two artificial tear formulations for dry eye through high‐resolution optical coherence tomography

2011

Purpose:  The aim was to determine the efficacy of two artificial eye-drop formulations by analysing the lower tear film meniscus volume through a commercial high-resolution spectral-domain optical coherence tomographer. Methods:  Twenty dry eye patients (12 men, eight women, aged 57.5 ± 8.4 years) with refractive errors from -2.50 to +0.75 D (mean -1.34 ± 1.02 D) and cylinders lower than 1.00 D were examined. Tear meniscus volume was measured before, immediately after and 10, 30 and 60 minutes after instillation using the Copernicus high-resolution spectral-domain optical coherence tomographer (Optopol Tech SA, Zawiercie, Poland). Volume was calculated from the local area obtained from tom…

Malemedicine.medical_specialtyDrug Compoundingmedicine.medical_treatmentDry Eye SyndromesHigh resolutionMeniscus (anatomy)Young AdultOptical coherence tomographyReference ValuesOphthalmologymedicineHumansSurface Tensionmedicine.diagnostic_testbusiness.industryImage Enhancementeye diseasesSurgeryOphthalmologyArtificial tearsmedicine.anatomical_structureVolume (thermodynamics)TearsTearsDry Eye SyndromesFemalesense organsEyelidOphthalmic SolutionsbusinessTomography Optical CoherenceFollow-Up StudiesOptometryClinical and Experimental Optometry
researchProduct